OGEN

Oragenics, Inc. is a development-stage company that is focused on fighting infectious diseases, including those caused by coronaviruses and multidrug-resistant organisms. The Company’s lead product NT-CoV2-1 is an intranasal vaccine candidate to prevent coronavirus disease (COVID-19) from the SARS-CoV-2 virus and variants thereof. Its lantibiotics program features a novel class of antibiotics against bacteria its research has shown may be applicable to multiple antibiotic-resistant organisms. Its Antibiotics product is a semi-synthetic analog of MU1140, which is a member of lantibiotic class of antibiotics. Through its wholly owned subsidiary, Noachis Terra, is engaged in the research and development stage for its new Terra CoV-2 and NT-CoV2-1 vaccine product candidates. It is also developing semi-synthetic lantibiotic analogs that may be effective against systemic Gram-positive multidrug infections, and analogs that may be effective in treating Gram-negative infections.